vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs 0.7%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $21.3M). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
AVNS vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $253.4M |
| Net Profit | $-1.3M | — |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 28.7% |
| Net Margin | -0.7% | — |
| Revenue YoY | 0.7% | 62.7% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $253.4M | ||
| Q3 25 | $177.8M | $244.7M | ||
| Q2 25 | $175.0M | $203.3M | ||
| Q1 25 | $167.5M | $174.6M | ||
| Q4 24 | $179.6M | $155.8M | ||
| Q3 24 | $170.4M | $148.5M | ||
| Q2 24 | $171.7M | $131.1M | ||
| Q1 24 | $166.1M | $118.5M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $51.5M | ||
| Q2 25 | $-76.8M | $46.5M | ||
| Q1 25 | $6.6M | $42.9M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $30.5M | ||
| Q2 24 | $1.8M | $25.7M | ||
| Q1 24 | $-900.0K | $26.4M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 28.7% | ||
| Q3 25 | 0.1% | 27.4% | ||
| Q2 25 | -42.6% | 29.5% | ||
| Q1 25 | 6.1% | 30.8% | ||
| Q4 24 | -233.0% | 28.9% | ||
| Q3 24 | 7.0% | 25.9% | ||
| Q2 24 | 3.7% | 25.5% | ||
| Q1 24 | 2.4% | 29.0% |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | 21.0% | ||
| Q2 25 | -43.9% | 22.9% | ||
| Q1 25 | 3.9% | 24.6% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | 20.5% | ||
| Q2 24 | 1.0% | 19.6% | ||
| Q1 24 | -0.5% | 22.3% |
| Q4 25 | $-0.02 | $2.05 | ||
| Q3 25 | $-0.03 | $1.87 | ||
| Q2 25 | $-1.66 | $1.68 | ||
| Q1 25 | $0.14 | $1.57 | ||
| Q4 24 | $-8.64 | $1.29 | ||
| Q3 24 | $0.09 | $1.15 | ||
| Q2 24 | $0.04 | $1.00 | ||
| Q1 24 | $-0.02 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $106.9M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $942.7M |
| Total Assets | $1.1B | $3.1B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $106.9M | ||
| Q3 25 | $70.5M | $111.7M | ||
| Q2 25 | $90.3M | $81.3M | ||
| Q1 25 | $97.0M | $119.3M | ||
| Q4 24 | $107.7M | $80.4M | ||
| Q3 24 | $89.0M | $86.5M | ||
| Q2 24 | $92.2M | $47.8M | ||
| Q1 24 | $75.8M | $61.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $942.7M | ||
| Q3 25 | $778.0M | $878.1M | ||
| Q2 25 | $776.3M | $847.2M | ||
| Q1 25 | $839.4M | $790.4M | ||
| Q4 24 | $828.5M | $729.0M | ||
| Q3 24 | $1.2B | $703.3M | ||
| Q2 24 | $1.2B | $532.6M | ||
| Q1 24 | $1.2B | $501.7M |
| Q4 25 | $1.1B | $3.1B | ||
| Q3 25 | $1.1B | $2.9B | ||
| Q2 25 | $1.0B | $2.8B | ||
| Q1 25 | $1.1B | $2.4B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.7B | $2.3B | ||
| Q2 24 | $1.7B | $2.0B | ||
| Q1 24 | $1.7B | $1.9B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $409.1M |
| Free Cash FlowOCF − Capex | $21.3M | $409.0M |
| FCF MarginFCF / Revenue | 11.8% | 161.4% |
| Capex IntensityCapex / Revenue | 3.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $409.1M | ||
| Q3 25 | $14.0M | $83.6M | ||
| Q2 25 | $6.8M | $120.9M | ||
| Q1 25 | $25.7M | $87.2M | ||
| Q4 24 | $57.9M | $261.2M | ||
| Q3 24 | $23.0M | $100.3M | ||
| Q2 24 | $27.8M | $55.1M | ||
| Q1 24 | $-8.0M | $33.1M |
| Q4 25 | $21.3M | $409.0M | ||
| Q3 25 | $7.0M | $83.6M | ||
| Q2 25 | $-4.2M | $120.8M | ||
| Q1 25 | $19.0M | $87.1M | ||
| Q4 24 | $53.1M | $260.9M | ||
| Q3 24 | $20.0M | $100.1M | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | 161.4% | ||
| Q3 25 | 3.9% | 34.2% | ||
| Q2 25 | -2.4% | 59.4% | ||
| Q1 25 | 11.3% | 49.9% | ||
| Q4 24 | 29.6% | 167.5% | ||
| Q3 24 | 11.7% | 67.4% | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 3.9% | 0.0% | ||
| Q2 25 | 6.3% | 0.0% | ||
| Q1 25 | 4.0% | 0.0% | ||
| Q4 24 | 2.7% | 0.2% | ||
| Q3 24 | 1.8% | 0.1% | ||
| Q2 24 | 3.4% | 0.0% | ||
| Q1 24 | 2.5% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.63× | ||
| Q2 25 | — | 2.60× | ||
| Q1 25 | 3.89× | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 3.29× | ||
| Q2 24 | 15.44× | 2.14× | ||
| Q1 24 | — | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PLMR
Segment breakdown not available.
